MX2021004425A - Vacuna contra cancer de cadena invariante de teleosteo. - Google Patents

Vacuna contra cancer de cadena invariante de teleosteo.

Info

Publication number
MX2021004425A
MX2021004425A MX2021004425A MX2021004425A MX2021004425A MX 2021004425 A MX2021004425 A MX 2021004425A MX 2021004425 A MX2021004425 A MX 2021004425A MX 2021004425 A MX2021004425 A MX 2021004425A MX 2021004425 A MX2021004425 A MX 2021004425A
Authority
MX
Mexico
Prior art keywords
invariant chain
polypeptides
teleost
polynucleotides
vectors
Prior art date
Application number
MX2021004425A
Other languages
English (en)
Inventor
Alfredo Nicosia
Elisa Scarselli
Armin Lahm
Original Assignee
Nouscom Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nouscom Ag filed Critical Nouscom Ag
Publication of MX2021004425A publication Critical patent/MX2021004425A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001111—Immunoglobulin superfamily
    • A61K39/001114—CD74, Ii, MHC class II invariant chain or MHC class II gamma chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/461—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from fish
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464401—Neoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464411—Immunoglobulin superfamily
    • A61K39/464414—CD74, Ii, MHC class II invariant chain or MHC class II gamma chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/605—MHC molecules or ligands thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a polipéptidos que comprenden un fragmento de una cadena invariante de teleósteo fusionada a uno o más antígenos o una cadena invariante de teleósteo fusionada a uno o más antígenos o fragmentos antigénicos de los mismos, un polinucleótido que codifica dichos polipéptidos, vectores que comprenden dichos polinucleótidos, una colección de vectores que comprenden dichos polinucleótidos y el uso de dichos polipéptidos, polinucleótidos, vectores para tratar o prevenir enfermedades, en particular enfermedades tumorales. Los polipéptidos de cadena invariante de teleósteo o fragmentos de los mismos actúan como "potenciadores de linfocitos T" que convierten secuencias antigénicas no inmunogénicas en antígenos de linfocitos T inmunogénicos.
MX2021004425A 2018-10-19 2019-10-18 Vacuna contra cancer de cadena invariante de teleosteo. MX2021004425A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18201541 2018-10-19
PCT/EP2019/078395 WO2020079234A1 (en) 2018-10-19 2019-10-18 Teleost invariant chain cancer vaccine

Publications (1)

Publication Number Publication Date
MX2021004425A true MX2021004425A (es) 2021-07-06

Family

ID=64270581

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021004425A MX2021004425A (es) 2018-10-19 2019-10-18 Vacuna contra cancer de cadena invariante de teleosteo.

Country Status (12)

Country Link
US (1) US20210379169A1 (es)
EP (1) EP3866848A1 (es)
JP (2) JP2022504315A (es)
KR (1) KR20210081325A (es)
CN (1) CN112955177A (es)
AU (1) AU2019361280A1 (es)
BR (1) BR112021003499A2 (es)
CA (1) CA3109541A1 (es)
IL (1) IL282429A (es)
MX (1) MX2021004425A (es)
SG (1) SG11202101735PA (es)
WO (1) WO2020079234A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202043256A (zh) 2019-01-10 2020-12-01 美商健生生物科技公司 前列腺新抗原及其用途
EP4137153A1 (en) 2021-08-18 2023-02-22 Sirion Biotech GmbH Therapeutic papilloma virus vaccines

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1711518T3 (pl) 2004-01-23 2010-06-30 St Di Richerche Di Biologia Molecolare P Angeletti S P A Nośniki szczepionek pochodzące od szympansich adenowirusów
HUE045093T2 (hu) * 2008-11-21 2019-12-30 Kobenhavns Univ University Of Copenhagen Immunválasz kiváltása
WO2010085984A1 (en) * 2009-02-02 2010-08-05 Okairos Ag Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof
BRPI1008018A2 (pt) 2009-02-02 2016-03-15 Okairos Ag ácidos nucleicos de adenovírus símio e sequências de aminoácidos, vetores contendo os mesmos e uso dos mesmos
GB201321384D0 (en) * 2013-12-04 2014-01-15 Isis Innovation Molecular adjuvant
CA3034124A1 (en) * 2016-08-23 2018-03-01 Glaxosmithkline Biologicals Sa Fusion peptides with antigens linked to short fragments of invariant chain (cd74)
CN110352071A (zh) * 2016-10-26 2019-10-18 库瑞瓦格股份公司 脂质纳米颗粒mRNA疫苗

Also Published As

Publication number Publication date
CA3109541A1 (en) 2020-04-23
JP2022504315A (ja) 2022-01-13
WO2020079234A1 (en) 2020-04-23
US20210379169A1 (en) 2021-12-09
EP3866848A1 (en) 2021-08-25
AU2019361280A1 (en) 2021-03-11
SG11202101735PA (en) 2021-03-30
BR112021003499A2 (pt) 2021-05-18
JP2024059879A (ja) 2024-05-01
KR20210081325A (ko) 2021-07-01
IL282429A (en) 2021-06-30
CN112955177A (zh) 2021-06-11

Similar Documents

Publication Publication Date Title
MX2023002858A (es) Prediccion de epitopos de celulas t utiles para vacunacion.
MX2021011687A (es) Composiciones inmunogenicas y vacunas que comprenden peptidos y proteinas del virus de la peste porcina africana y usos de las mismas.
PH12019502151A1 (en) T cell receptors and immune therapy using the same against prame positive cancers
MX2020001996A (es) Moleculas anti-cd137 y uso de estas.
CY1122178T1 (el) Πολυπεπτιδια
ZA201904723B (en) Population-based immunogenic peptide identification platform
PE20191081A1 (es) Nuevos receptores de celulas t y terapia inmunologica que los utiliza
PH12019501241A1 (en) Novel t cell receptors and immune therapy using the same
MX2020010701A (es) Péptidos antigénicos para la prevención y el tratamiento del cáncer.
PH12017500484A1 (en) Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (hcc) and other cancers
MX2019001769A (es) Nuevos receptores de linfocitos t e inmunoterapia basada en el uso de los mismos.
MX361728B (es) Ácido nucleico que comprende o codifica un tallo-bucle de histona y una secuencia poli(a) o una señal de poliadenilación para incrementar la expresión de un antígeno tumoral codificado.
ES2337399T3 (es) Peptidos asociados a tumores unidos promiscuamente a moleculas del antigeno de leucocito humano (hla) de clase ii.
MX2017004729A (es) Terapia de combinacion para usar en la terapia contra el cancer.
MX2021004425A (es) Vacuna contra cancer de cadena invariante de teleosteo.
MX2022005704A (es) Peptidos antigenicos para la prevencion y el tratamiento de malignidad de celulas b.
ATE404669T1 (de) In brust- und blasenkrebs differentiell exprimiertes gen und durch dieses kodierte polypeptide
MX2022003658A (es) Vacunas contra el virus de la hepatitis b (vhb) y metodos para tratar el vhb.
BR112018073221A2 (pt) métodos de previsão da utilidade de proteínas ou seus fragmentos, métodos de seleção e/ou avaliação de modificações de aminoácidos específicas, método de fornecimento de vacinas e vacina
NZ609916A (en) Hla-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof
MX2020004552A (es) Vacuna potenciadora de celulas t.
SG11201903800XA (en) ANTIBODY BINDING SPECIFICALLY TO CD66c AND USE THEREOF
MX2020001287A (es) Receptor de linfocitos t (tcrs) especificos de braf y usos de los mismos.
CO2018001985A2 (es) Polipéptidos mrka, anticuerpos y usos de los mismos
MX2020005188A (es) Nuevos peptidos y nueva combinacion de peptidos para el uso en la inmunoterapia contra el carcinoma hepatocelular (chc) y otros tipos de cancer.